The Arab Drug Company (EGX:ADCI)

Verve Therapeutics Cash Flow Statement

Financials in millions EGP. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Net Income	184.99	102.82	82.77	76.3	101.41	92.8
Depreciation & Amortization	26.52	10.91	3.26	9.39	7.81	0.73
Other Operating Activities	-56.23	22.03	1.48	-52.82	-72.65	-20.3
Operating Cash Flow	155.29	135.77	87.51	32.87	36.58	73.24
Operating Cash Flow Growth	24.90%	55.15%	166.22%	-10.14%	-50.05%	99.96%
Capital Expenditures	-127.91	-218.95	-63.18	-89.92	-28.87	-2.53
Investment in Securities	-67.03	-67.03	-	13.88	-	-0.7
Other Investing Activities	27.7	27.92	1.07	1.63	4.34	1.84
Investing Cash Flow	-167.25	-258.07	-62.11	-74.41	-24.53	-1.4
Short-Term Debt Issued	-	-	-	27.33	-	-
Long-Term Debt Issued	-	339.09	51.3	52.54	-	-
Total Debt Issued	23.87	339.09	51.3	79.87	-	-
Long-Term Debt Repaid	-	-44.55	-	-	-	-
Total Debt Repaid	-107.06	-44.55	-	-	-	-
Net Debt Issued (Repaid)	-83.19	294.54	51.3	79.87	-	-
Common Dividends Paid	-59.62	-36.1	-37.49	-43.54	-38.85	-32.2
Other Financing Activities	-46.32	-23.09	-1.68	-0.95	-	-
Financing Cash Flow	-189.13	235.35	12.13	35.38	-38.85	-32.2
Miscellaneous Cash Flow Adjustments	58.24	69.18	-27.33	-	-0	-
Net Cash Flow	-142.85	182.24	10.2	-6.15	-26.8	39.64
Free Cash Flow	27.38	-83.19	24.33	-57.04	7.71	70.7
Free Cash Flow Growth	-	-	-	-	-89.09%	123.21%
Free Cash Flow Margin	2.67%	-10.59%	3.84%	-11.29%	1.44%	13.58%
Free Cash Flow Per Share	2.28	-6.93	2.03	-4.21	0.56	4.76
Cash Interest Paid	46.32	23.09	1.68	0.95	-	-
Cash Income Tax Paid	45.64	34.73	35.09	51.95	52.97	24.45
Levered Free Cash Flow	-49.69	-110.04	-24.95	-121.56	-1.96	51.41
Unlevered Free Cash Flow	-20.74	-95.61	-23.5	-120.96	-1.93	51.41
Change in Net Working Capital	76.21	-38.62	24.26	97.17	57.25	20.09

Source: S&P Global Market Intelligence. Standard template. Financial Sources.